Your browser doesn't support javascript.
loading
Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition.
Kennedy, Amanda J; Sundström, Linda; Geschwindner, Stefan; Poon, Eunice K Y; Jiang, Yuhong; Chen, Rongfeng; Cooke, Rob; Johnstone, Shawn; Madin, Andrew; Lim, Junxian; Liu, Qingqi; Lohman, Rink-Jan; Nordqvist, Anneli; Fridén-Saxin, Maria; Yang, Wenzhen; Brown, Dean G; Fairlie, David P; Dekker, Niek.
Afiliação
  • Kennedy AJ; Mechanistic Biology & Profiling, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Sundström L; MSD at the Francis Crick Institute, London, UK.
  • Geschwindner S; Mechanistic Biology & Profiling, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Poon EKY; Structure & Biophysics, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Jiang Y; Centre for Inflammation and Disease Research (CIDR) and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, 4072, Australia.
  • Chen R; Centre for Inflammation and Disease Research (CIDR) and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, 4072, Australia.
  • Cooke R; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, 100176, Beijing, People's Republic of China.
  • Johnstone S; Sosei Heptares, Steinmetz Building, Granta Park, Great Abington, Cambridge, CB21 6DG, UK.
  • Madin A; Department of Chemistry, IntelliSyn Pharma, 7171 Frederick-Banting, Montreal, QC, H4S 1Z9, Canada.
  • Lim J; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
  • Liu Q; Centre for Inflammation and Disease Research (CIDR) and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, 4072, Australia.
  • Lohman RJ; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, 100176, Beijing, People's Republic of China.
  • Nordqvist A; Centre for Inflammation and Disease Research (CIDR) and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, 4072, Australia.
  • Fridén-Saxin M; Medicinal Chemistry, Cardiovascular, Renal & Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Yang W; Alliance & Project Management, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Brown DG; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, 100176, Beijing, People's Republic of China.
  • Fairlie DP; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Boston, MA, USA.
  • Dekker N; Centre for Inflammation and Disease Research (CIDR) and ARC Centre of Excellence in Advanced Molecular Imaging, Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, 4072, Australia.
Commun Biol ; 3(1): 782, 2020 12 17.
Article em En | MEDLINE | ID: mdl-33335291
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptor PAR-2 / Regulação Alostérica / Sítio Alostérico / Ligantes Idioma: En Revista: Commun Biol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Suécia País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptor PAR-2 / Regulação Alostérica / Sítio Alostérico / Ligantes Idioma: En Revista: Commun Biol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Suécia País de publicação: Reino Unido